Edition:
United States

CymaBay Therapeutics Inc (CBAY.O)

CBAY.O on Consolidated Issue listed on NASDAQ Capital Market

4.24USD
29 Mar 2017
Change (% chg)

$0.15 (+3.67%)
Prev Close
$4.09
Open
$4.05
Day's High
$4.32
Day's Low
$4.05
Volume
506,593
Avg. Vol
439,105
52-wk High
$4.44
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

CymaBay reports Q4 and year end 2016 financial results
Thursday, 23 Mar 2017 04:01pm EDT 

CymaBay Therapeutics Inc - : CymaBay reports fourth quarter and year end 2016 financial results . Q4 loss per share $0.30 . Q4 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S . As of December 31, 2016, CymaBay had cash, cash equivalents and marketable securities of approximately $17.0 million .Believes that funds, among others, will allow co to continue operations through at least next twelve months.  Full Article

Cymabay announces pricing of public offering of common stock
Thursday, 2 Feb 2017 09:15am EST 

Cymabay Therapeutics Inc : Cymabay announces pricing of public offering of common stock .Says public offering of 5.18 million common shares priced at $1.93per share.  Full Article

CymaBay reports proposed public offering of common stock
Wednesday, 1 Feb 2017 04:01pm EST 

Cymabay Therapeutics Inc : CymaBay announces proposed public offering of common stock .Anticipates using net proceeds from offering to fund ongoing development of seladelpar.  Full Article

Kowa Pharmaceuticals enters agreement with CymaBay Therapeutics to license gout compound
Tuesday, 3 Jan 2017 04:01pm EST 

Kowa Pharmaceuticals America Inc : Kowa Pharmaceuticals America Inc announces agreement with CymaBay Therapeutics to license gout compound . Kowa Pharmaceuticals America - will license product from CymaBay, which has completed a combined 17 phase 1 and phase 2 studies in over 1,100 subjects . Kowa Pharmaceuticals America - CymaBay will receive pre-specified milestone and sales-related payments . Kowa Pharmaceuticals America - under terms of agreement, co will manage Phase 3 clinical development program for arhalofenate .Kowa Pharmaceuticals America - under terms of agreement, co will commercialize arhalofenate upon approval of arhalofenate in combination with febuxostat in U.S..  Full Article

Cymabay reports second quarter 2016 financial results
Tuesday, 9 Aug 2016 04:01pm EDT 

Cymabay Therapeutics Inc : Q2 loss per share $0.30 . Cymabay reports second quarter 2016 financial results .Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Cymabay qtrly loss per share $0.29
Wednesday, 11 May 2016 04:05pm EDT 

Cymabay Therapeutics Inc : Qtrly loss per share $0.29 .Cymabay reports first quarter 2016 financial results.  Full Article

CymaBay Therapeutics announces the appointment of Robert J. Wills, Ph.D., as Chairman
Thursday, 8 Oct 2015 04:01pm EDT 

CymaBay Therapeutics:Says Robert J. Wills, Ph.D., a member of the Board of Directors since March 2015, has been appointed Chairman of the Board of Directors.Wills replaces retiring Chairman, Louis G. Lange, M.D., Ph.D.  Full Article

CymaBay Therapeutics Inc strengthens intellectual property of Arhalofenate with issuance of two new patents
Thursday, 6 Aug 2015 08:00am EDT 

CymaBay Therapeutics Inc:Sasy US Patent and Trademark Office (USPTO) has issued two new patents for Arhalofenate, CymaBay's lead product candidate for the treatment of gout.These patents are expected to provide additional protection for arhalofenate through at least 2032 before accounting for any potential patent term extension.  Full Article

CymaBay announces completion of public offering of common stock
Monday, 27 Jul 2015 04:01pm EDT 

CymaBay Therapeutics Inc:Says it has completed the previously announced public offering of common stock.Sold 8,188,000 common shares in the offering, including the 1,068,000 common shares that were issued upon the full exercise by the underwriters of their over-allotment option.Offering price was $2.81 per share, and the gross proceeds to CymaBay from the sale of the shares, including the over-allotment option, were about $23 mln.Net proceeds to CymaBay were about $21 mln.Piper Jaffray & Co. acted as the sole book-running manager for the offering, and LifeSci Capital LLC acted as the lead manager.  Full Article

CymaBay Therapeutics Inc prices it's public offering of common stock
Wednesday, 15 Jul 2015 09:10am EDT 

CymaBay Therapeutics Inc:Announces pricing of $20 million public offering of common stock.Says public offering of 7.1 million common shares priced at $2.81 per share.  Full Article

More From Around the Web